Skip to main content
Donate

Every penny really does count.

DONATE

You are here

Company stock-piling supplies of diabetes treatments as UK prepares to leave European Union

Company stock-piling supplies of diabetes treatments as UK prepares to leave European Union

‘Life saving’ diabetes products being collected over fear of implications of a no-Brexit deal.

Published: Oct 05, 2018
Category: Diabetes
Share:

A Surrey-based healthcare supplier of to the NHS for people with diabetes has doubled its stock of treatments in the event of a no-Brexit deal.

As previously reported with uncertainty surrounding whether an agreeable trade deal will be met before the UK leaves the European Union (EU) in March next year, pharmaceutical companies had been urged to stock up on medical supplies over Brexit deal uncertainty.

GlucoRx has heeded that warning, with the company having already stockpiled 12 months’ worth of “life-saving products,” including glucometers, test strips, lancets and pen needles.

In addition, the government has asked GlucoRx’s Managing Director to provide his thoughts on how failure to reach an agreement could impact the supply of medical devices and clinical consumables to people who need them.

Chris Chapman, Group Managing Director of GlucoRx

Chris Chapman, Group Managing Director of GlucoRx, said: “We are already facing delays of up to four weeks at Southampton Port. This is because more and more companies across the UK are also stock-piling their products ahead of the UK exit from the EU in March, with the current climate suggesting we may leave without a trade deal in place, which is a major concern.”

GlucoRx is worried that uncertainty over the impact of leaving the European Union has led medical supply companies to fear long delays at customs checks at British ports, that could severely disrupt the logistics chain, slowing down supply deliveries and therefore putting patients’ lives at risk.

Mr Chapman added: “This is a worrying time and we know how vital these life-saving products are to people with diabetes. That’s why we’re committed to delivering these items to our customers and putting a contingency plan in place now, whatever happens.

“I will be sure to convey our concerns, along with all our back-up plans to the Secretary of State for Health and Social Care, who has asked me for my thoughts on how a no deal EU exit could impact supplying our medical devices on a long-term basis and what measures we’re taking to ensure our customers’ health is not affected.”

The company has recently sourced additional warehouse facilities as well as stockpiling the products at several existing locations. 

Prime Minister Theresa May was recently dealt a setback after she failed to attract EU backing for her Brexit plan during an informal gathering of European leaders in Austria.

Under the Chequers plan, as agreed by ministers in July, the Prime Minister hopes to agree a “common rulebook” between Britain and the EU on goods, as well as new customs arrangements with the trade bloc.

The Association of Medical Research Charities, of which DRWF is a member, are working to ensure that the voice of the medical research charity sector is heard as part of this process and have called for “no disruption in the supply of medicines and treatments”. Read more here

Read the Medicines and Healthcare products Regulatory Agency (MHRA) response to exiting the EU
Category: Diabetes
Share:
×

Share this